Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBITDA Margin over the past 16 years, most recently at 14.62% for Q2 2025.

  • Quarterly results put EBITDA Margin at 14.62% for Q2 2025, up 894.0% from a year ago — trailing twelve months through May 2025 was 13.38% (down 2995.0% YoY), and the annual figure for FY2025 was 13.38%, down 649.0%.
  • EBITDA Margin for Q2 2025 was 14.62% at Lifecore Biomedical, Inc. \De\, up from 25.68% in the prior quarter.
  • Over the last five years, EBITDA Margin for LFCR hit a ceiling of 47.16% in Q4 2023 and a floor of 149.47% in Q4 2021.
  • Median EBITDA Margin over the past 5 years was 23.5% (2023), compared with a mean of 29.83%.
  • Biggest five-year swings in EBITDA Margin: crashed -10073bps in 2023 and later soared 18136bps in 2024.
  • Lifecore Biomedical, Inc. \De\'s EBITDA Margin stood at 149.47% in 2021, then skyrocketed by 62bps to 57.26% in 2022, then skyrocketed by 182bps to 47.16% in 2023, then crashed by -113bps to 6.02% in 2024, then soared by 343bps to 14.62% in 2025.
  • The last three reported values for EBITDA Margin were 14.62% (Q2 2025), 25.68% (Q1 2025), and 6.02% (Q4 2024) per Business Quant data.